相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).
C. S. Karapetis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
FLIPL induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity
Cristina Pop et al.
BIOCHEMICAL JOURNAL (2011)
Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents
Christina Menke et al.
CANCER RESEARCH (2011)
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Jianfeng Lu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor Cells
Liping Xu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis
Andrew Oberst et al.
NATURE (2011)
TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro
Christina Menke et al.
PLOS ONE (2011)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
H. A. Wakelee et al.
ANNALS OF ONCOLOGY (2010)
In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide
Andrew E. Logan et al.
APOPTOSIS (2010)
Death Receptor Agonists as a Targeted Therapy for Cancer
Jeffrey Wiezorek et al.
CLINICAL CANCER RESEARCH (2010)
Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Howard M. Stern et al.
CLINICAL CANCER RESEARCH (2010)
Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang et al.
CLINICAL CANCER RESEARCH (2010)
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL receptor signaling and therapeutics
Junaid Abdulghani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Overcoming TRAIL resistance in ovarian carcinoma
Kerri S. Bevis et al.
GYNECOLOGIC ONCOLOGY (2010)
Inducible Dimerization and Inducible Cleavage Reveal a Requirement for Both Processes in Caspase-8 Activation
Andrew Oberst et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
Bernhard Gillissen et al.
JOURNAL OF CELL BIOLOGY (2010)
A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
J. Von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TRAILing death in cancer
Gregory Mellier et al.
MOLECULAR ASPECTS OF MEDICINE (2010)
MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers
J. S. Imam et al.
ONCOGENE (2010)
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
C. R. Reis et al.
CELL DEATH & DISEASE (2010)
LY303511 Enhances TRAIL Sensitivity of SHEP-1 Neuroblastoma Cells via Hydrogen Peroxide-Mediated Mitogen-Activated Protein Kinase Activation and Up-regulation of Death Receptors
Kirthan Shenoy et al.
CANCER RESEARCH (2009)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Constantijne H. Mom et al.
CLINICAL CANCER RESEARCH (2009)
Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
Tae-Jin Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition
Erica L. McCoy et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling
Douglas S. Micalizzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
John Yee et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
Stephen Leong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins
Henrick Horita et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation
Ricardo D. Coletta et al.
CANCER RESEARCH (2008)
Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis
P. Makhov et al.
CELL DEATH AND DIFFERENTIATION (2008)
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2008)
Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
D. Ross Camidge
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis
Jin H. Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Quercetin Sensitizes Human Hepatoma Cells to TRAIL-Induced Apoptosis Via Sp1-Mediated DR5 Up-Regulation and Proteasome-Mediated c-FLIPS Down-Regulation
Jin Yeop Kim et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas
M. N. Saleh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
FLIP as an anti-cancer therapeutic target
Jin Kuk Yang
YONSEI MEDICAL JOURNAL (2008)
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2
Alessandro Natoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding
Lianghua Bin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner et al.
NATURE MEDICINE (2007)
Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
Faiy H. Psahoulia et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Who should be sent for genetic testing in hereditary colorectal cancer syndromes?
Henry T. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival
Kian Behbakht et al.
CANCER RESEARCH (2007)
Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein
Collins A. Karikari et al.
MOLECULAR CANCER THERAPEUTICS (2007)
TRAIL signalling: Decisions between life and death
Christina Falschlehner et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
A. Trauzold et al.
ONCOGENE (2006)
The c-FLIP-NH2 terminus (p22-FLIP) induces NF-κB activation
Alexander Golks et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
cFLIP regulation of lymphocyte activation and development
RC Budd et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells
JK Earel et al.
CANCER RESEARCH (2006)
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
TJ Sayers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae
S Martin et al.
CANCER RESEARCH (2005)
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
S Ray et al.
APOPTOSIS (2005)
Cutting edge: TRAIL deficiency accelerates hematological malignancies
N Zerafa et al.
JOURNAL OF IMMUNOLOGY (2005)
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
M MacFarlane et al.
CELL DEATH AND DIFFERENTIATION (2005)
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer
P Horak et al.
MOLECULAR CANCER RESEARCH (2005)
c-FLIPR, a new regulator of death receptor-induced apoptosis
A Golks et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells
JM Cummins et al.
CANCER RESEARCH (2004)
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis
ZY Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells
FA Sinicrope et al.
CLINICAL CANCER RESEARCH (2004)
TRAIL-R as a negative regulator of innate immune cell responses
GE Diehl et al.
IMMUNITY (2004)
Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice
SJ Zheng et al.
JOURNAL OF IMMUNOLOGY (2004)
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells
M Taniai et al.
CANCER RESEARCH (2004)
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity
MS Ricci et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes
S Ehrlich et al.
CYTOKINE (2003)
Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway
ES Henson et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB
H Ehrhardt et al.
ONCOGENE (2003)
Cell surface death receptor signaling in normal and cancer cells
N Özören et al.
SEMINARS IN CANCER BIOLOGY (2003)
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis
Y Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
S Fulda et al.
ONCOGENE (2002)
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
E Cretney et al.
JOURNAL OF IMMUNOLOGY (2002)
Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc et al.
NATURE MEDICINE (2002)
TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy
LF Lincz et al.
LEUKEMIA (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
FC Kischkel et al.
IMMUNITY (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
分享论文
